NKTR NEKTAR THERAPEUTICS

Nasdaq nektar.com


$ 60.50 $ -0.32 (-0.56 %)    

Tuesday, 14-Oct-2025 19:55:18 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 57.08
$ 56.21
$ 58.50 x 300
$ 62.00 x 95
$ 55.50 - $ 58.29
$ 6.48 - $ 62.95
720,091
na
1.09B
$ 1.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-14-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-06-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 02-26-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 02-28-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-01-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-01-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-01-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-04-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 b-riley-securities-maintains-buy-on-nektar-therapeutics-raises-price-target-to-105

B. Riley Securities analyst Mayank Mamtani maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price targe...

 btig-reiterates-buy-on-nektar-therapeutics-maintains-100-price-target

BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $100 price target.

 nektar-therapeutics-announces-new-data-from-ongoing-rezolve-ad-phase-2b-study-of-rezpegaldesleukin-at-2025-eadv-congress

Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitisHigh dose rezpega...

 whats-going-on-with-nektar-therapeutics-stock-on-thursday

Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.

 b-riley-securities-maintains-buy-on-nektar-therapeutics-raises-price-target-to-85

B. Riley Securities analyst Mayank Mamtani maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price targe...

 nektar-therapeutics-prices-underwritten-public-offering-of-100m-of-shares-at-2350shr

Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in...

 us-stock-futures-slip-after-two-days-of-record-advances-fomo-could-add-another-5-10-says-expert

U.S. futures slipped on Tuesday after two days of record-setting advances. Futures of major benchmark indices were trading lower.

 why-is-nektar-therapeutics-stock-trading-higher-on-wednesday

Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differe...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION